Intestinal permeability of lamivudine using single pass intestinal perfusion

Indian Journal of Pharmaceutical Sciences

Volumn 74, Issue 5, 2012, Pages 478-481

  Patel, J R ^a   Barve, Kalyani H ^a  

^a SVKM s Narsee Monjee Institute of Management Studies   (India)

Author keywords

Biopharmaceutic classification system; drug permeability; lamivudine; single pass intestinal perfusion

Indexed keywords

LAMIVUDINE;

ARTICLE; DRUG CLASSIFICATION; DRUG EXPOSURE; FLOW RATE; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; INTESTINE PERFUSION; NONHUMAN; WISTAR RAT;

EID: 84875952709     PISSN: 0250474X     EISSN: 19983743     Source Type: Journal    
DOI: 10.4103/0250-474X.108441     Document Type: Article

References (26)

1. Anonymous. The British Pharmacopoeia. Vol. 2. United Kingdom: The Stationary Office on Behalf of the Medicine and Healthcare Products Regulatory Agency (MHRA); 2008. p. 1216-8.
2. Anonymous. United States Pharmacopoeia/National Formulary. Asian Edition. Rockville: The United States Pharmacopeial Convention; 2006. p. 1225-6.
3. Beale JM. Antiviral agents. In: Wilson and Gisvold's Textbook of Organic Medicinal Chemistry. 11 th ed. New York: Lippincot Williams and Wilkims; 2004. p. 381-2.
4. Brunton LL, Lazo JS, Parker KL. Antimicrobial agents. In: Goodman and Gilman's The Pharmacological Basics of Therapeutics. 11 th ed. New York: The McGraw-Hill Companies; 2008. p. 1264-5, 1288-9.
5. Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 1999;36:41-66.
6. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asian Hepatitis Lamivudine Study Group. N Engl J Med 1998;339:61-8.
7. Anonymous. General notes on biopharmaceutics classification system (BCS)-based biowaiver applications. WHO Prequalification of Medicines Programme; 2008. p. 1.
8. Amidon GL, Sinko PJ, Fleisher D. Estimating human oral fraction dose absorbed: A correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm Res 1988;5:651-4.
9. Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 1991;175:880-5.
10. Hillgren KM, Kato A, Borchardt RT. In vitro systems for studying intestinal drug absorption. Med Res Rev 1995;15:83-109.
11. Salphati L, Childers K, Pan L, Tsutsui K, Takahashi L. Evaluation of a single-pass intestinal-perfusion method in rat for the prediction of absorption in man. J Pharm Pharmacol 2001;53:1007-13.
12. Fagerholm U, Johansson M, Lennernäs H. Comparison between permeability coefficients in rat and human jejunum. Pharm Res 1996;13:1336-42.
13. Barthe L, Woodley J, Houin G. Gastrointestinal absorption of drugs: Methods and studies. Fundam Clin Pharmacol 1999;13:154-68.
14. Song NN, Li QS, Liu C. Intestinal permeability of metformin using single-pass intestinal perfusion in rats. World J Gastroenterol 2006;12:4064-70.
15. Cook TJ, Shenoy SS. Intestinal permeability of chlorpyrifos using the single-pass intestinal perfusion method in the rat. Toxicology 2003;184:125-33.
16. Xu YA, Fan G, Gao S, Hong Z. Assessment of intestinal absorption of vitexin-2"-o-rhamnoside in hawthorn leaves flavonoids in rat using in situ and in vitro absorption models. Drug Dev Ind Pharm 2008;34:164-70.
17. Cutler DJ. Theory of the mean absorption time, an adjunct to conventional bioavailability studies. J Pharm Pharmacol 1978;30:476-8.
18. Yao GX, Shen ZY, Xue XB, Yang Z. Intestinal permeability in rats with CCl 4-induced portal hypertension. World J Gastroenterol 2006;12:479-81.
19. Amidon GL, Lennernäs H, Shah VP, Crison Jr. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413-20.
20. Svensson US, Sandström R, Carlborg O, Lennernäs H, Ashton M. High in situ rat intestinal permeability of artemisinin unaffected by multiple dosing and with no evidence of P-glycoprotein involvement. Drug Metab Dispos 1999;27:227-32.
21. Komiya I, Park JY, Kamani A, Ho NF, Higuchi WI. Quantitative mechanistic studies in simultaneous fluid flow and intestinal absorption using steroids as model solutes. Int J Pharm 1980;4:249-62.
22. Takamatsu N, Welage LS, Idkaidek NM, Liu DY, Lee PI, Hayashi Y, et al. Human intestinal permeability of piroxicam, propranolol, phenylalanine, and PEG 400 determined by jejunal perfusion. Pharm Res 1997;14:1127-32.
23. Lennernas H, Knustson L, Knutson R, Lesko L, Salmonson T, Amidon GL. Human effective permeability data for atenolol, metoprolol, propranolol, desipramine and carbamazepine to be used in the proposed biopharmaceutical classification for IR-products. Eur J Pharm Sci 1996;4:S69.
24. Volpe DA, Moller H, Yu LX. Regulatory acceptance of in vitro permeability studies in the context of the biopharmaceutics classification system. In: Lehr CM, editor. Cell Culture Models of Biological Barriers: In Vitro Test Systems for Drug Absorption and Delivery. London, New York: Taylor and Francis Publishing Group; 2002 p. 130-9.
25. Zakeri-Milani P, Valizadeh H, Tajerzadeh H, Azarmi Y, Islambolchilar Z, Barzegar S, et al. Predicting human intestinal permeability using single-pass intestinal perfusion in rat. J Pharm Pharm Sci 2007;10:368-79.
26. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system, guidance for industry. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), August 2000.